Structured population data were available for 4 of 4 supporting studies. 3 studies described participants with type 2 diabetes. 4 studies described adult participants.

1 supporting study does not have a displayable topic-matched quantitative effect.

Evidence uses heterogeneous comparison contexts: active_comparator, baseline_within_group.

Pioglitazone 15 mg/day;Glimepiride 2 mg/day

Empagliflozin 10 mg/day;Glimepiride 2 mg/day

Empagliflozin 10 mg/day;Pioglitazone 15 mg/day

Core clinician-reference fields are available or not applicable.

Participants received empagliflozin as a third-line therapy in addition to ongoing metformin and DPP-4 inhibitors.

Empagliflozin 10 mg/day

Participants were randomised to receive empagliflozin 10 mg/day ( n = 61)

Participants received pioglitazone as a third-line therapy in addition to ongoing metformin and DPP-4 inhibitors.

Pioglitazone 15 mg/day

Participants were randomised to receive pioglitazone 15 mg/day ( n = 58)

Participants received glimepiride as a third-line therapy in addition to ongoing metformin and DPP-4 inhibitors.

Glimepiride 2 mg/day

Participants were randomised to receive glimepiride 2 mg/day ( n = 57)

Adding medications improves blood sugar control in diabetes patients.

Available source content was suppressed because validation identified a conflict.

Glimepiride group

Patients received empagliflozin for 12 weeks after initial treatment.

Empagliflozin group

The empagliflozin group ( n = 33) showed no significant differences in ΔFMDs.

Patients received glimepiride for 12 weeks after initial treatment.

The glimepiride group ( n = 30) showed no significant differences in ΔFMDs.

Authoritative quality diagnostic: invalid or missing unit.

Authoritative quality diagnostic: invalid or missing value.

Empagliflozin reduces body fluid volume in type 2 diabetes patients

Not extracted from the authoritative source.

Clinician-reference record is usable with limitations in: comparator.

Patients received insulin glargine in the morning with fixed doses of metformin.

Insulin glargine plus metformin

After 24 weeks, HbA1C levels improved from (mean ± SD) 8.5±0.9% to 7.7±0.8% (69.0±10.0 mmol/mol to 60.8±8.6 mmol/mol) with insulin glargine plus metformin.

Patients received insulin glargine in the morning with fixed doses of glimepiride.

Insulin glargine plus glimepiride

After 24 weeks, HbA1C levels improved from 8.4±1.0% to 7.7±1.3% with insulin glargine plus glimepiride.

Patients received insulin glargine in the morning with fixed doses of both glimepiride and metformin.

Insulin glargine plus glimepiride plus metformin

After 24 weeks, HbA1C levels improved from 8.7±0.9% to 7.3±0.6% with insulin glargine plus glimepiride plus metformin.

Insulin glargine plus metformin and glimepiride improves glycemic control in type 2 diabetes.

Glimepiride

Participants received once-daily linagliptin 5 mg as an add-on to metformin for 8 weeks.

Linagliptin

In this predefined substudy within a randomized, double-blind, parallel-group, intervention trial, overweight people with T2D without renal impairment were treated with once-daily linagliptin 5 mg (N=10) as an add-on to metformin for 8 weeks.

Participants received once-daily glimepiride 1 mg as an add-on to metformin for 8 weeks.

In this predefined substudy within a randomized, double-blind, parallel-group, intervention trial, overweight people with T2D without renal impairment were treated with once-daily glimepiride 1 mg (N=13) as an add-on to metformin for 8 weeks.

Glimepiride × HbA1c

Available supporting studies

Adding medications improves blood sugar control in diabetes patients.

Empagliflozin reduces body fluid volume in type 2 diabetes patients

Insulin glargine plus metformin and glimepiride improves glycemic control in type 2 diabetes.

Linagliptin may increase postprandial renal hyperfiltration in type 2 diabetes